Ph.D. Michael Exton - 06 Nov 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

SEC form
4
Accepted by SEC
09 Nov 2026, 08:13:49 UTC
Prior SEC filing
03 Mar 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Ph.D. Michael Exton filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 09 Nov 2026.

Key facts

  • This page summarizes Ph.D. Michael Exton's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Nov 2026, 08:13.

Change

  • Previous filing in this sequence was filed on 03 Mar 2026.
  • Current net transaction value: +$49,999.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002029249 Primary reporting owner

Exton Michael

Relationship
Chief Executive Officer, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX transaction

Common Stock

Purchase

Transaction value
$49,999
Shares
+30,064
Change %
+10%
Price
$1.66
Shares after
328,496
Date
06 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.67 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .